Skip to main content
Clinical Trials/NCT05090397
NCT05090397
Completed
Not Applicable

Applied Strategies for MRI-Guided High-Definition tDCS for Major Depression

Northwestern University1 site in 1 country26 target enrollmentJuly 1, 2023
ConditionsDepression

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Depression
Sponsor
Northwestern University
Enrollment
26
Locations
1
Primary Endpoint
Changes in brain functional connectivity
Status
Completed
Last Updated
last year

Overview

Brief Summary

The purpose of this research is to understand how a neurostimulation technique, transcranial electrical stimulation (tES), affects brain function in adults with major depression measured with functional magnetic resonance imaging (fMRI). This study targets a specific kind of tES called transcranial direct current stimulation (tDCS), where a mild, constant current is passed between electrodes placed on the scalp.

Detailed Description

This is an investigator-initiated MRI research study of a noninvasive neurostimulation technique, transcranial direct current stimulation (tDCS) using focal "high definition" (HD) electrodes positioned using pre-treatment MRI. Primary objective is to measure changes in brain function during MRI-guided HDtDCS with MRI. Secondary objective is to measure changes in depressive symptoms after five consecutive days of MRI-guided tDCS (20 minutes per session).

Registry
clinicaltrials.gov
Start Date
July 1, 2023
End Date
March 31, 2025
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Amber Leaver

Research Associate Professor

Northwestern University

Eligibility Criteria

Inclusion Criteria

  • Ages between 18 and 65
  • Race/ethnicity: all races and ethnic groups
  • Sex/Gender: all
  • Capacity to provide informed consent
  • Diagnosis of Major Depressive Disorder made by volunteer's physician at least one year prior (confirmed by patient self-report)
  • Currently under the care of a clinician for depression (psychiatrist, psychologist, or other clinician)
  • Currently experiencing symptoms of depression (Patient Health Questionnaire 9, PHQ9 \>4 at screening; Hamilton Depression Rating Scale 17-item, HDRS-17, score \>8 at Visit 1)
  • Stable or no pharmacological antidepressant regimen (SSRI, SNRI, MOAI, or tricyclic/TCA) with no change in treatment 6 weeks prior to study start

Exclusion Criteria

  • Ages below 18 (neurobiology is quite different in children vs. adults)
  • Ages above 65 (cortical excitability changes with age)
  • Active suicidal thoughts, ideation, or behavior with plan within the past month (HDRS-17 item 3 score 3-4)
  • Change in antidepressant medication within 6 weeks of study start
  • Diagnosis of any medical condition potentially affecting brain function: neuropsychiatric or mental disorders, other mood disorders (bipolar disorder, primary anxiety disorder, PTSD), psychotic states or disorders, developmental disorders, neurological disorders, including mild cognitive impairment, significant head injury, significant history of alcohol/substance abuse or dependence within past 12 months, chronic pain (current, or for more than one year within the past one year), other major medical conditions (e.g., cancer, stroke).
  • MRI contraindications: metal or other implants that are not MR-safe, claustrophobia, pregnancy or suspected pregnancy
  • tES contraindications: skin conditions or injuries on the scalp hair extensions, wigs, braids, etc. that cannot be removed prior to the study, metal implants or pacemakers (also contraindicated for MRI)
  • Non-English speakers (due to written consent and questionnaires administered)
  • Neurostimulation or neuromodulation treatment for any reason within the past 3 months
  • Current medication use potentially affecting brain function, including decongestants, antihistamines, benzodiazepines or other anticonvulsants, anti-psychotics.

Outcomes

Primary Outcomes

Changes in brain functional connectivity

Time Frame: Acute/immediate

Functional MRI will measure changes in brain function during tDCS. Specifically, the investigators will measure change in functional connectivity of prefrontal cortex (% change in Fisher's z).

Secondary Outcomes

  • Changes in depressive symptoms (Beck)(1 week, 2 weeks, 1 month)
  • Changes in depressive symptoms (Hamilton)(1 week, 2 weeks, 1 month)

Study Sites (1)

Loading locations...

Similar Trials